中国生物：sIPV疫苗获批上市 “五联苗”获批临床

Core Viewpoint - The recent advancements in vaccine development by China National Pharmaceutical Group's Wuhan Institute of Biological Products signify a crucial step in the country's efforts to combat major infectious diseases and enhance the self-reliance in high-end combination vaccines [1] Group 1: Vaccine Approvals - The Sabin strain inactivated poliovirus vaccine (Vero cell) has received approval for market launch from the National Medical Products Administration (NMPA) [1] - The combined vaccine for acellular pertussis, diphtheria, tetanus, inactivated poliovirus, and Haemophilus influenzae type b has been granted clinical trial approval [1]